The efficacy of combination of ondansetron and aprepitant on preventing the radiotherapy-induced nausea and vomiting

• Published in: Journal of research in medical sciences Vol. 20; no. 4; pp. 329 - 333
• Main Authors: Emami, Hamid, Hematti, Simin, Saeidian, Seyed, Feizi, Awat, Taheri, Shahin, Adeli, Pourya, Mahmoudi, Golshan
• Format: Journal Article
• Language: English
• Published: India Medknow Publications Pvt Ltd 01.04.2015; Medknow Publications & Media Pvt Ltd; Wolters Kluwer Medknow Publications
• Subjects: Aprepitant; nausea and vomiting; ondanseton; Original; radiotherapy; radiotherapy-induced nausea and vomiting; Aprepitant; radiotherapy; ondanseton; radiotherapy-induced nausea and vomiting; nausea and vomiting
• ISSN: 1735-1995; 1735-1995; 1735-7136
• DOI: 10.4103/1735-1995.158244

Background: Depending on the site of irradiation, about 40-80% of patients undergoing radiotherapy (RT) will experience nausea and/or vomiting. The current study aimed to investigate the efficacy of ondansetronas as a single agent and with a combination to aprepitant on preventing RT-induced nausea and vomiting (RINV). Materials and Methods: In a clinical randomized controlled trial (from September 2010 to September 2011), conducted in Radiation Oncology Department of Seyed-al-Shohada Hospital, Isfahan University of Medical Sciences, 40 abdominopelvic malignancies cancer patients were allocated into two aliquots using block randomization of size. Patients in the first group (group I) received ondansetron alone while those patients in the remaining group (group II) received ondansetron and aprepitant. Then, developing of RINV and its severity and benefit of adding aprepitant to ondansetron, in comparison with ondansetron as a single drug therapy were evaluated. Results: The average age of the patients in group I was 61.15 ± 12.27 years while in group II it was 50.1 ± 13.27 years. No statistically significant gender differences were found between the two groups. In patients treated with ondansetron single drug therapy (group I), frequency and grade of RINV were significantly more than the group treated simultaneously by aprepitant and ondansetron (group II) (odds ratio [OR] = 21.2; P < 0.01). Compared with RT alone, the patients whom underwent RT along with chemotherapy showed lower probability of experiencing RINV (OR = 0.13; P < 0.05). Conclusion: The present study indicated a significant superiority of combination of ondansetron and aprepitant in management of RINV, in patients undergoing RT, compared to ondansetron as a single agent therapy. More accurate follow-up studies are needed for the evaluation of the efficacy of ondansetron with combination to aprepitant on preventing the RINV.